Summary
The recent outbreak of monkeypox outside its endemic boundaries has attracted global attention and prompted world leaders to reserve thousands of doses of the only approved third-generation smallpox/monkeypox vaccine Jynneos, which is based on the highly attenuated modified vaccinia Ankara (MVA) vector. Given the potential urgency to vaccinate individuals at risk in both endemic and non-endemic countries to curtail further spread of the outbreak, there is a legitimate need for substantial doses of smallpox/monkeypox vaccines. We previously developed COH04S1, a multiantigen SARS-CoV-2 vaccine candidate built on a synthetic MVA platform. COH04S1 was found to be safe and to induce SARS-CoV-2-specific immune responses in healthy adults participating in a phase 1, blinded, randomized, placebo-controlled clinical trial. Here we perform a retrospective analysis of vaccine-induced orthopoxvirus immunity in a subgroup of volunteers enrolled in the phase 1 clinical trial that were vaccinated with COH04S1 at different doses. At all dose levels, vaccination with COH04S1 resulted in robust MVA-specific binding and neutralizing antibody responses, which were sustained over six months post-vaccination. Similarly, both CD8+ and CD4+ T cells specific for MVA were induced by COH04S1 vaccination and remained durable for at least six months. Given that both arms of the immune response are thought to be involved in protection against orthopoxvirus infections, our results indicate that COH04S1 or other sMVA-based vaccines may represent valuable candidates for smallpox/monkeypox vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04639466
Funding Statement
The Carol Moss Foundation provided funding for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the City of Hope National Medical Center gave full ethical approval of this work under COHIRB#20447.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
